Abstract

Pharmaceutical composition containing combination of a non-steroidal anti- inflammatory drugs (NSAIDs) and of an effective amount decongestant and further comprising suitable pharmaceutically acceptable carriers or excipients in the form of powder or granules for making hot drink solution with water.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

Dietary food supplements; Dietary supplements; Food for babies; Medical dressings; Medical plasters; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of the cardiovascular diseases and disorders; Sanitary preparations for medical use; Veterinary pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system and the cardiovascular system

Abstract

90) ranging from 1 μm to 100 μm.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/14 - Particulate form, e.g. powders

Abstract

The present invention relates to pharmaceutical compositions comprising the active substance Lenalidomide in one of the modifications selected from Lenalidomide base, a Lenalidomide salt, a Lenalidomide cocrystal or mixtures thereof, wherein the Lenalidomide particles have a particle size distribution (d90) ranging from 1µm to 100µm.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to pharmaceutical compositions comprising the active substance Lenalidomide in one of the modifications selected from Lenalidomide base, a Lenalidomide salt, a Lenalidomide cocrystal or mixtures thereof, wherein the Lenalidomide particles have a particle size distribution (d90) ranging from 1µm to 100µm.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Improvements in the preparation process of 3-(4-amino-1-oxo-1,3-dihydro-2H- isoindol-2-yl)piperidine-2,6-dione (Ienalidomide), wherein the intermediate 2-methyl- 3-nitrobenzoic acid methyl ester is brominatcd with N-bromosuccinimide in methyl acetate and the end product is obtained from 3-(4-nitro-l-oxo-l,3-dihydro- 2H-isoindol-2-yl)piperidine-2,6-dione by reducing with iron and ammonium chloride reducing system.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts to decrease blood plasma levels of insulin and glucose.

IPC Classes  ?

• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• C07C 227/08 - Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Abstract

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts to decrease blood plasma levels of insulin and glucose.

IPC Classes  ?

• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• C07C 227/08 - Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Abstract

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts: 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium hydrogen fumarate and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate, in the prevention and treatment atherosclerosis.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts: 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium hydrogen fumarate and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate, in the prevention and treatment atherosclerosis.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention provides the use of 3-(2,2,2-trimethylhydrazinium)-ethylpropionate or a pharmaceutically acceptable salt in the treatment of increased intraocular pressure.

IPC Classes  ?

• A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

4-Oxo-2-phenylaminopyrimidine derivatives as intermediates for synth of tyrosine kinase inhibitors, in particular imatinib and nilotinib.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Abstract

Antiviral efficacy of disodium 2,6-dimethyl-1,4-dihydropyridine-3,5- bis(carbonyloxyacetate) and its derivatives (compound with general formula I) wherein R is hydrogen, methyl or ethyl.

IPC Classes  ?

• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, method of preparation thereof and use in the treatment of cardiovascular disease.

IPC Classes  ?

• C07C 55/10 - Succinic acid
• C07C 57/15 - Fumaric acid
• C07C 69/86 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
• C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07D 239/557 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

4-[(Haloalkyl)(dimethyl)ammonio]butanoates of formula (I) wherein Hal is Cl or F, n=1 or 2, method for preparing thereof and use thereof for treating cardiovascular disease.

IPC Classes  ?

• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, method of preparation thereof and use in the treatment of cardiovascular disease.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07C 55/10 - Succinic acid
• C07C 57/15 - Fumaric acid
• C07C 69/86 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
• C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07D 239/557 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Abstract

The invention relates to the 5R,4R-enantiomer of 2-(5-methyl-2-oxo-4-phenyl- pyrrolidin-1-yl)-acetamide with cognition enhancing activity of high pharmacological value and to its preparation method.

IPC Classes  ?

• C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

New 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid ester type compounds having general formula (I), wherein R is hydrogen or carboxylate-methyl ester, R1 is sodium carboxylate-methyl ester, R2 is methyl, ethyl or sodium carboxylate-methyl ester, possessing antiviral efficacy.

IPC Classes  ?

• C07D 211/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The invention relates to the 5S,4R-enantiomer of 2-(5-methyl-2-oxo-4-phenyl- pyrrolidin-1-yl)-acetamide with cognition enhancing activity of high pharmacological value and to its preparation method which includes the synthesis of 5S-methyl-4R-phenylpyrrolidin-2-one, its N-alkylation with ethyl haloacetate and the treatment of intermediate ethyl 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetate with ammonia.

IPC Classes  ?

• C07D 207/263 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.

IPC Classes  ?

• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Abstract

New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.

IPC Classes  ?

• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A pharmaceutical composition with cardioprotective, antiischemic, antihypoxic and antioxidant properties for prevention and/or treatment of disorders, selected from the group of dyslipidemia, hyperlipidemia, atherosclerosis, coronary heart disease as chosen from the group of angina pectoris and myocardial infarction, chronic heart failure, transient and permanent ischemic attack including cerebrovascular accident and stroke and peripheral arterial occlusive disease, comprising Meldonium succinate alone or in the combination with inorganic succinate.

IPC Classes  ?

• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61P 3/06 - Antihyperlipidemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Gamma-butyrobetaine succinate and pharmaceutical composition thereof. New pharmaceutical composition relates to prevention and/or treatment of a disorder selected from a group, consisting of dyslipidemia, hyperlipidemia, atherosclerosis, chronic heart failure, transient and permanent ischemic attack including cerebrovascular accident and stroke and peripheral arterial occlusive disease.

IPC Classes  ?

• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 3/06 - Antihyperlipidemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Pharmaceutical composition of gamma-butyrobetaine and Meldonium dihydrate and its use in prevention and/or treatment of atherosclerosis and/or neurological diseases.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Stable pharmaceutical composition containing Fludarabine phosphate as active ingredient.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets

Abstract

Use of Meldonium dihydrate (3-(2,2,2-trimethylhydrazinium)propionate dihydrate) or its pharmaceutically acceptable salts for prevention and/or treatment of Parkinson's disease.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 25/16 - Anti-Parkinson drugs

Abstract

New compounds of 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid ester type having general formula (I) wherein R is a lower alkyl group, which is methyl or ethyl R1 and R2 is sodium carboxylate-methyl ester, having synergistic cytotoxic effect combined with 5-fluorouracil.

IPC Classes  ?

• C07D 211/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Abstract

A gel composition for the topical, local administration of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate through the skin comprises 3-(2,2,2-trimethylhydrazinium) propionate dihydrate in a concentration of about 2.5% to 10% and Carbomer. The composition also comprises pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention provides pharmaceutical combination of phenolic compound, such as caffeic acid phenethyl ester and cancer chemotherapeutic agent, such as 1-(2-tetrahydrofuryl)-5-fluorouracil. In one embodiment of the present invention, pharmaceutical combination of caffeic acid phenethyl ester and 1-(2-tetrahydrofuryl)-5-fluorouracil can be used for inhibition of tumor metastases.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The invention provides an improved, efficient method for preparing3-(2,2- dimethylhydrazino)methylpropionate.

IPC Classes  ?

• C07C 241/02 - Preparation of hydrazines
• C07C 243/14 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton

Abstract

The invention provides an improved, efficient method for preparing 3- (2,2,2- trimethylhydrazinium) propionate dihydrate from 3- (2,2, 2-trimethylhydrazinium) propionate methylsulphate.

IPC Classes  ?

• C07C 241/02 - Preparation of hydrazines
• C07C 243/40 - Hydrazines having nitrogen atoms of hydrazine groups being quaternised

Abstract

The present invention relates to one-pot process for preparing 3-(2,2,2-trimethylhydrazinium)propionate dihydrate from 3-(2,2-dimethylhydrazino)propionate esters.

IPC Classes  ?

• C07C 241/02 - Preparation of hydrazines
• C07C 243/40 - Hydrazines having nitrogen atoms of hydrazine groups being quaternised

Abstract

The present invention relates to carbonic and sulphuric salts of 3-(2,2,2-trimethylhydrazinium)propionate esters and their use for the preparation of 3- (2,2,2-trimethylhydrazinium)propionate dihydrate.

IPC Classes  ?

• C07C 241/02 - Preparation of hydrazines
• C07C 243/40 - Hydrazines having nitrogen atoms of hydrazine groups being quaternised

Abstract

The present invention relates to use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for the treatment of impotentia generandi.

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to highly effective treatment of cardiovascular diseases with 3-(2,2,2-trimethylhydrazinium)propionate orotate.

IPC Classes  ?

• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to highly effective treatment of ischemic heart disease with 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate, and 3-(2,2,2-trimethylhydrazinium) propionate dihydrogen phosphate.

IPC Classes  ?

• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention provides an improved, highly efficient method for preparing 5-(2- ethyl-2,3-dihydro-1 H-inden-2-yl)-1 H-imidazole, and its salts, in particular its pharmaceutically acceptable salts.

IPC Classes  ?

• C07D 233/58 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms

Abstract

The invention provides an improved, highly efficient method for preparing 5-(2- ethyl-2,3-dihydro-1 H-inden-2-yl)-1 H-imidazole, and its salts, in particular its pharmaceutically acceptable salts.

IPC Classes  ?

• C07D 233/58 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms

Abstract

Novel medical use of 3-(2,2,2-trimethylhydraziniunn) propionate salts for the manufacture of a medicament for prevention and therapy of atherosclerosis.

IPC Classes  ?

• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention provides an improved, highly efficient method for preparing Medetomidine, and its salts, in particular its pharmaceutically acceptable salts. The method utilizes the high reactivity of halogenated imidazoles towards transmetalation with Grignard reagents and the subsequent reaction with 2,3- dimethylbenzaldehyde.

IPC Classes  ?

• C07D 233/54 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Abstract

The present invention relates to a process for the preparation of 2,5-bis(2,2,2-trifluoroethoxy)toluene (II). The compound 2,5-bis(2,2,2-trifluoroethoxy)toluene is useful as intermediate for pharmaceutical industry, especially useful as an intermediate for the preparation of Flecainide and pharmaceutically acceptable salts.

IPC Classes  ?

• C07C 41/01 - Preparation of ethers
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring

Abstract

Process for the preparation of 2,5-bis(2,2,2-trifluoroethoxy)-N-(2- piperidylmethyl)benzamide, its pharmaceutically acceptable salts and important intermediates thereof that involves 1,4-dihalotoluenes as starting material. The method involves a technique for preparing the starting material 2,5-bis(2,2,2-trifluroethoxy)toluene in high yields by reacting 1,4- dibromotoluene with 2,2,2-trifluoroethanol in presence of a base and a copper-containing catalyst.

IPC Classes  ?

• C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Abstract

The invention provides an improved, highly efficient method for preparing Medetomidine, and its salts, in particular its pharmaceutically acceptable salts. The method utilizes the high reactivity of halogenated imidazoles towards transmetalation with Grignard reagents and the subsequent reaction with 2,3- dimethylbenzaldehyde.

IPC Classes  ?

• C07D 233/54 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members